A possible step by the Food and Drug Administration (FDA) to address safety concerns in a new experimental drug law could limit drug companies wanting to fast-track unrelated and potentially groundbreaking medicines.
Study the topic in more depth in the AAPS book Regulated Bioanalysis: Fundamentals and Practice.
To read the full content, please log in with your AAPS member username and password.
Sign InNot a member? Learn more and join today!
AAPS Newsmagazine helps pharmaceutical scientists excel in their jobs by providing current science, news, career advice, member recognition, AAPS offerings, and other valuable contemporary information.
2107 Wilson Blvd. #700
Arlington, VA 22201
AAPS Customer Service